Denise Neves Gameiro, Author at Labiotech.eu

About

Journalist intern. Studied Bioengineering in Porto and was a lab rat in Sweden. Enjoying Berlin and the company of Labiotech’s resident plants.

Articles by Denise Neves Gameiro

News and Trends 13 Apr 2016

Leading Biotech VC in Europe Raises over €180M

Forbion has raised €183M for its 3rd capital fund – a big win for this top-notch Dutch VC, especially when stock markets are getting ever less friendly. Forbion is one of the best European VCs in Europe for Biotech. Based primarily near Amsterdam (it also has offices in Munich), it is probably a factor in […]

April 13, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 13 Apr 2016

A New Cellular ‘Back Door’ has been found to fight Malaria

Paris & Strasbourg (France) researchers have discovered an ‘Achilles Heel’ for malaria: A specific molecule the parasite needs from the host. Could this spawn a new generation of Parasitic disease drugs? Malaria is a parasitic disease that was responsible for over 400,000 deaths worldwide just in 2015, according to the WHO – especially in sub-Saharan Africa. However, the current […]

April 13, 2016 - 3 minutesmins - By Denise Neves Gameiro

europe biotech ey finance growth pharma industry 2016

News and Trends 12 Apr 2016

How was the Biotech Financial World in 2015? Unprecedented!

Biotech is still breaking funding records. A new report by EY provides an interesting analysis of how Biotech is doing, globally and in Europe. Although 2015 was the best for Biotech yet, but there is a slowdown coming – that’s the gist of EY’s recent report: ‘Beyond borders 2016: Biotech financing‘. This well-known auditing and […]

April 12, 2016 - 3 minutesmins - By Denise Neves Gameiro

Genentech birthday 40 biotechnology cohen boyer swanson

News and Trends 11 Apr 2016

Modern Biotechnology is Now 40 – Happy Birthday!

Genentech has turned 40 years old this month – quite a milestone for the pioneer of modern biotechnology, which is still rocking it in San Francisco, US. It all began with an experiment conducted by a team led by Herbert Boyer of the University of California San Francisco (UCSF), studying antibiotic resistance plasmids in E. […]

April 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

medday multiple sclerosis neurodegenerative disease md1003

News and Trends 11 Apr 2016

French Biotech gets €34M to bring Multiple Sclerosis Drug to the US

MedDay (France) has raised €34M that should help pay a US phase III for its leading candidate for Multiple Sclerosis – as well as its commercial launch in Europe. Based in Paris, MedDay is a Biotech developing new drugs targeting brain metabolism to treat diseases of the nervous system. Its leading candidate, MD1003, has a mixed track record. […]

April 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

lipigon astrazeneca lipoprotein lipase lpl cardiovascular

News and Trends 11 Apr 2016

Swedish Startup close to the North Pole signs 100 million deal with AstraZeneca

Lipigon Pharmaceuticals will now count with AstraZeneca to push the development of its Lipoprotein Lipase strategies. This could produce novel drugs to tackle metabolic and cardiovascular disease, still the leading cause of death worldwide. Lipigon is a spinout of Umeå University, developing new drugs based on research of lipid metabolism. Umeå may have one of the most remote universities […]

April 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

center genomic gastronomy denfeld kramer

News and Trends 9 Apr 2016

BioArt & Genomic Gastronomy: Glowing Sushi, ‘Smog Tasting’ and Gamma Gardens

The Center for Genomic Gastronomy in Dublin (Ireland) curates an unusual type of BioArt which makes us think about how we see food and technology – through fluorescent sushi, ‘Smog candy’ and radiation-bred sauces. Describing themselves as an ‘artist-led think tank‘, the Center for Genomic Gastronomy (CGG for short) is making witty projects that range from cook-offs and […]

April 9, 2016 - 5 minutesmins - By Denise Neves Gameiro

heptares allergan neurological alzheimer gpcr

News and Trends 7 Apr 2016

Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech

Heptares Therapeutics is licensing its portfolio of novel candidates for neurological diseases, including one for Alzheimer’s, to Allergan for up to €3Bn. A good way for Allergan to ‘get over’ yesterday’s failed Pfizer acquisition. Based in Cambridge, UK, Heptares Therapeutics is creating new therapies with their StaR platform, that allows it to target G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to many […]

April 7, 2016 - 3 minutesmins - By Denise Neves Gameiro

morphosys galapagos inflammatory mor106 mab

News and Trends 7 Apr 2016

Two of the Biggest European Biotechs launch Antibody Program together

MorphoSys (Germany) and Galapagos (Belgium) have announced a new joint program to conduct a phase I trial for a first-in-class antibody, MOR106, that could be used to treat inflammatory diseases. Just after announcing that it is suing Janssen Biotech and Genmab (Denmark), Munich-based MorphoSys is still keeping things interesting – this time with a phase I trial for […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

tunicates pharma mar sea squirt alplidin trial cancer multiple myeloma

News and Trends 7 Apr 2016

This Successful Phase III Cancer Drug comes from Sea Squirts

PharmaMar is closer to have another cancer drug on the market, after the success of phase III trials with Aplidin for Multiple Myeloma. Based in Madrid, PharmaMar is a Biopharma developing anti-cancer drugs, with an interesting strategy for drug discovery. It researches compounds present in marine organisms and assess if they have any biological action […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

aleksandra elbakyan scihub opensource science publishing revoliuton

News and Trends 6 Apr 2016

This 27-year-old Woman is Shaking up the Scientific Publishing Industry

During my studies, I was always frustrated by the pay-walls standing between my assignments and the references I needed to access. Alexandra Elbakyan is trying to solve this problem. This 27-year-old woman had the skills (and guts) to create SciHub, the ‘Napster of scientific publication’. The scientific publication industry is generating $10Bn annual revenues, has margins around 30% and is controlled by […]

April 6, 2016 - 5 minutesmins - By Denise Neves Gameiro

samsung bioepis biotech rheumatoid arthritis biosimilar flixabi sb4

News and Trends 5 Apr 2016

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

Samsung Bioepis (South Korea) has gotten an approval recommendation from the EMA for one of its 13 in-development biosimilars: Flixabi, a biosimilar of Janssen’s blockbuster Remicade for Inflammatory diseases. Samsung Bioepis is a joint venture between Biogen and Samsung BioLogics, a branch of the Korean giant that provides manufacturing services for development of biologicals. It started developing […]

April 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Denise Neves Gameiro

About

Articles by Denise Neves Gameiro

Leading Biotech VC in Europe Raises over €180M

A New Cellular ‘Back Door’ has been found to fight Malaria

How was the Biotech Financial World in 2015? Unprecedented!

Modern Biotechnology is Now 40 – Happy Birthday!

French Biotech gets €34M to bring Multiple Sclerosis Drug to the US

Swedish Startup close to the North Pole signs 100 million deal with AstraZeneca

BioArt & Genomic Gastronomy: Glowing Sushi, ‘Smog Tasting’ and Gamma Gardens

Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech

Two of the Biggest European Biotechs launch Antibody Program together

This Successful Phase III Cancer Drug comes from Sea Squirts

This 27-year-old Woman is Shaking up the Scientific Publishing Industry

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Denise Neves Gameiro

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!